Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 4—April 2011


Effects of Vaccination against Pandemic (H1N1) 2009 among Japanese Children

Cite This Article


Highlight and copy the desired format.

EID Nishiura H, Oshitani H. Effects of Vaccination against Pandemic (H1N1) 2009 among Japanese Children. Emerg Infect Dis. 2011;17(4):746-747.
AMA Nishiura H, Oshitani H. Effects of Vaccination against Pandemic (H1N1) 2009 among Japanese Children. Emerging Infectious Diseases. 2011;17(4):746-747. doi:10.3201/eid1704.100525.
APA Nishiura, H., & Oshitani, H. (2011). Effects of Vaccination against Pandemic (H1N1) 2009 among Japanese Children. Emerging Infectious Diseases, 17(4), 746-747.

To the Editor: We report findings from a household-based study on the protective effects of vaccination against pandemic (H1N1) 2009 among Japanese children. In Japan, prioritized vaccination started in October 2009, focusing on health care workers, pregnant women, persons with underlying diseases, and children 1–9 years of age. Only nonadjuvant split vaccines (inactivated) produced by 4 manufacturers (Denka Seiken, Tokyo, Japan; Kaketsuken, Kumamoto-shi, Japan; Kitasato, Tokyo, Japan; and Biken, Suita-shi, Japan) were used by the end of January 2010 (1). Because the protective effects of vaccination at the individual level are best measured by household data (2), we conducted a retrospective household survey involving 1,614 nonrandomly sampled households (i.e., based on area sampling of households across Japan, according to the regional population size, with a total of 6,356 household members), in which the earliest cases were diagnosed from October 2009 to mid-February 2010. Our study aimed to assess vaccine-induced reductions in susceptibility and infectiousness among children by using the household secondary attack rate.

Influenza cases were defined as confirmed cases (i.e., diagnosed by real-time PCR) or influenza-like illness (ILI) cases (i.e., in febrile patients [>37.5°C] with cough and/or sore throat). The cases had to meet the following inclusion criteria for analyses: 1) index case-patient and exposed persons in households were healthy children 1–9 years of age (households with <2 children were excluded), because age-specific susceptibility and infectiousness can greatly influence the frequency of household transmission (36); b) all exposed persons shared the same household with index case-patients for at least 1 of 7 days after illness onset of the index case-patient; c) index case-patient did not receive treatment with antiviral agents (e.g., zanamivir or oseltamivir) within 2 days after illness onset; d) time interval from illness onset of the index case-patient to that of subsequent case-patients was <7 days (7,8); and e) vaccinated persons received their first vaccination >28 days before illness onset (if index case-patient) or exposure (if not index case- patient).

In total, 251 children met the above criteria, comprising 109 index case-patients and 133 unvaccinated and 9 vaccinated exposed persons. The mean age was 6.4 ± 2.1 SD years. Among the 251 children, 15 (6.0%) had been vaccinated, and 169 (67.3%) had received a diagnosis of influenza. Confirmed cases accounted for 17.8% (30/169) of cases; 21 patients were the index case-patients in individual households. The mean age of patients with confirmed diagnoses was 6.5 ± 2.0 SD years and did not differ significantly from the ILI patients.

Let SARij represent the household secondary attack rate (SAR) with vaccination statuses of the index patient j and exposed persons i (where i or j is 0 or 1 for unvaccinated or vaccinated, respectively), and let b represent both groups. Among 133 exposed unvaccinated children, ILI developed in 59, yielding an SAR0b of 44.4%. Among 9 exposed vaccinated children, ILI developed in 1 child, yielding an SAR1b of 11.1%. The difference between these SARs was marginally significant (p = 0.08 by Fisher exact test), and the susceptibility reduction was 1 – SAR1b/SAR0b = 75.0% (95% confidence interval [CI] –60.5% to 96.1%). Considering only exposures caused by unvaccinated first patients, SAR00 and SAR10 were 44.7% (59/132) and 0% (0/4), respectively. When the first patients with ILI in households were unvaccinated, ILI was observed in 59 of 136 children, yielding an SARb0 of 43.4%. Among 6 exposures caused by vaccinated first patients, ILI developed in 1 person, yielding an SARb1 of 16.7%. Although not significant (p = 0.40), the reduction in infectiousness by vaccination was estimated to be 1 – SARb1/SARb0 = 61.6% (95% CI –132.3% to 93.6%). The SAR01 was 0% (i.e., 1 exposure to an unvaccinated person caused by a vaccinated first patient did not result in influenza). Limiting the definition of influenza to confirmed cases, all 8 exposures to vaccinated persons did not result in influenza, and SAR0b and SAR1b were 10.8% and 0%, respectively. Similarly, all 5 exposures caused by vaccinated first patients did not result in confirmed cases, and SARb0 and SARb1 were 10.5% and 0%, respectively.

Although the CIs of the estimates included zero because of the small sample size, the expected reductions in susceptibility and infectiousness were 75.0% and 61.6%, respectively, which is consistent with findings from a meta-analysis of vaccine efficacy against seasonal influenza (9). Two limitations must be noted, namely, estimates based on nonrandom samples and a case definition that relied on symptoms of case-patients. The former point cannot be explicitly addressed by a retrospective study design, but we enforced strict inclusion criteria for analyses and limited our study to healthy children. Accounting for the latter point (e.g., serologic diagnosis to capture symptomatic and asymptomatic cases) could yield slightly higher estimates than ours, provided that vaccination reduces the probability of clinical illness if infection occurs. Thus, despite these limitations and a critical need for further studies that include estimations of effectiveness (10), our results provide insight into the effects of vaccination in reducing risks for infection and clinical attack among children exposed to pandemic (H1N1) 2009 virus in their households.

Hiroshi NishiuraComments to Author  and Hitoshi Oshitani

Author affiliations: Author affiliations: Japan Science and Technology Agency, Saitama, Japan (H. Nishiura); University of Utrecht, Utrecht, the Netherlands (H. Nishiura); and Tohoku University Graduate School of Medicine, Sendai, Japan (H. Oshitani)


The work of H.N. was supported by the Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology program. O.H. received a Health and Labour Sciences Research Grant (20-005-OH) from the Ministry of Health, Labour and Welfare, Japan.


  1. Ministry of Health. Labour and Welfare, Japan. Vaccination against pandemic influenza(A/H1N1). 2009 [cited 2010 Mar 10].
  2. Halloran ME, Longini IM, Struchiner CJ. Design and analysis of vaccine studies. New York: Springer; 2010.
  3. Longini IM, Koopman JS, Haber M, Cotsonis GA. Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. Am J Epidemiol. 1988;128:84559.PubMed
  4. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingworth TD, Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009;324:155761. DOIPubMed
  5. Nishiura H, Chowell G, Safan M, Castillo-Chavez C. Pros and cons of estimating the reproduction number from early epidemic growth rate of influenza A (H1N1) 2009. Theor Biol Med Model. 2010;7:1. DOIPubMed
  6. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:10215.PubMed
  7. Cauchemez S, Donnelly CA, Reed C, Ghani AC, Fraser C, Kent CK, Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med. 2009;361:261927. DOIPubMed
  8. Morgan OW, Parks S, Shim T, Blevins PA, Lucas PM, Sanchez R, Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April–May 2009. Emerg Infect Dis. 2010;16:6317.PubMed
  9. Basta NE, Halloran ME, Matrajt L, Longini IM. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008;168:134352. DOIPubMed
  10. Smith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ, Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2006; (1):CD004879.PubMed
Cite This Article

DOI: 10.3201/eid1704.100525

Related Links

Table of Contents – Volume 17, Number 4—April 2011


Please use the form below to submit correspondence to the authors or contact them at the following address:

Hiroshi Nishiura, University of Utrecht, Yalelaan 7, Utrecht, 3584 CL, the Netherlands

character(s) remaining.

Comment submitted successfully, thank you for your feedback.